All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
EBMT 2018 | CCR5 and CXCR3 blockade attenuation of murine aGvHD
The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) took place in Lisbon, Portugal, on 18–21March 2018. On Monday 19 March, an abstract was presented titled “Combined CCR5 and CXCR3 blockade attenuates murine aGvHD through alternating donor-derived T-cell distribution and function” by Bo Tang from Peking University First Hospital, Beijing, China.
Chemokines are important mediators to control migratory patterns and positioning of all immune cells. Chemokine receptors play an essential role in directing the migration of donor derived T-cells to target organs. CXCR3 and CCR5 are chief among these chemokine receptors. Tang et al. investigated whether combined CCR5 and CXCR3 blockade could attenuate murine acute graft-versus-host disease (aGvHD), and also explored the immunologic mechanism behind it.
In order to establish an allogeneic bone marrow transplantation model, BALB/c (H-2Kd) recipients received 8.0 Gy of total body irradiation (TBI) prior to transplantation, followed by the infusion of bone marrow cells (BMCs) and splenic cells (SCs) from C57BL/6J (H-2Kb) or CCR5 knockout mice (H-2Kb).
Key findings:
- CCR5 and CXCR3 are enhanced during the aGvHD process
- CCR5 and CXCR3 blockade reduced aGvHD scores from 4.67±0.33 to 1.25±0.25, P < 0.001
- CCR5 and CXCR3 blockade reduced aGvHD related death from 90% to 40%, P < 0.05
- Compared with GvHD group, combined CCR5 and CXCR3 blockade reduced
- liver histologic score 3.3±0.3 vs 3±0.3, P < 0.05
- lung histologic score 3.6±0.3 vs 3±0.3, P < 0.05
- intestine histologic score 3.7±0.3 vs 3±0.3, P < 0.05
The speaker concluded by highlighting that combined CCR5 and CXCR3 blockade decreased the probability of aGvHD. Moreover, inhibition of aGvHD significantly associated with alternated donor T-cell distribution, limited donor T-cell activation and also reduced T-cell effector function in vivo. Tang further added that their data suggested that “the combined use of CCR5 and CXCR3 blockade might be applicable for aGvHD prophylaxis in clinical settings.”
References
Your opinion matters
When would you be most likely to consider prescribing belumosudil third-line and beyond?